Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Topical glucocorticoids with improved benefit/risk ratio: do they exist?

H C Korting1, M J Kerscher, M Schäfer-Korting

  • 1Dermatologische Klinik und Poliklinik, Ludwig-Maximilians-Universität, Munich, F.R.G.

Journal of the American Academy of Dermatology
|July 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Toxicity of topically applied drugs beyond skin irritation: Static skin model vs. Two organs-on-a-chip.

International journal of pharmaceutics·2020
Same author

Enhanced topical delivery of dexamethasone by β-cyclodextrin decorated thermoresponsive nanogels.

Nanoscale·2017
Same author

Influence of the skin barrier on the penetration of topically-applied dexamethasone probed by soft X-ray spectromicroscopy.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V·2016
Same author

Core-multishell nanocarriers: Transport and release of dexamethasone probed by soft X-ray spectromicroscopy.

Journal of controlled release : official journal of the Controlled Release Society·2016
Same author

Catch-up validation study of an in vitro skin irritation test method based on an open source reconstructed epidermis (phase II).

Toxicology in vitro : an international journal published in association with BIBRA·2016
Same author

Skin penetration and dermal tolerability of acrylic nanocapsules: Influence of the surface charge and a chitosan gel used as vehicle.

International journal of pharmaceutics·2016

Newer topical glucocorticoids, like prednicarbate, show promise for treating inflammatory skin conditions with fewer side effects. Research focuses on developing safer dermatologicals with improved benefit-risk profiles.

Area of Science:

  • Dermatology
  • Pharmacology
  • Drug Development

Background:

  • Topical glucocorticoids are widely used for inflammatory skin diseases due to their efficacy.
  • Concerns about systemic and topical side effects, particularly skin atrophy, limit their use.
  • There is a critical need for dermatologicals with an improved benefit-risk ratio.

Purpose of the Study:

  • To review the chemistry, pharmacology, clinical benefits, and toxicology of existing and novel glucocorticoids.
  • To highlight newer glucocorticoid congeners with a potentially better safety profile.
  • To discuss future alternatives in dermatological treatment.

Main Methods:

  • Review of existing literature on topical glucocorticoids.
  • Analysis of in vitro and in vivo studies on new drug candidates.

Related Experiment Videos

  • Inclusion of human studies using ultrasound for skin thickness assessment.

    • Main Results:

    • Newer nonfluorinated double-ester glucocorticoids, such as prednicarbate, demonstrate potential.
    • These novel agents appear to have less impact on fibroblast growth and skin thickness compared to conventional glucocorticoids.
    • Ultrasound findings in humans support the reduced side effect profile of new agents.

    Conclusions:

    • The development of safer topical glucocorticoids with an enhanced benefit-risk ratio is achievable.
    • Nonfluorinated double-ester glucocorticoids represent a promising advancement in dermatological therapy.
    • Ongoing research aims to identify and validate safer alternatives for inflammatory skin conditions.